BioSpace News Archive

TearClear Corp., an emerging Ophthalmic Pharmaceutical Company, has announced the appointment of Amir Shojaei, Pharm.D., Ph.D., as Chief Development Officer, a major step towards planning and executing multiple clinical development and registration programs.

Morgan Stanley executive brings extensive life sciences sector strategic and financial expertise to pioneering proteomics company

Surface Oncology announced it has entered into a clinical trial collaboration with Merck, known as MSD outside the United States and Canada, through a subsidiary, to evaluate the safety and efficacy of combining Surface’s SRF617, an investigational antibody therapy targeting CD39, with Merck’s KEYTRUDA®, the first anti-PD-1 therapy approved in the United States.

Spring Bank Pharmaceuticals, Inc. announced that a trial in progress poster will be presented for the Phase 1a/1b trial of the company’s intravenously-administered STING agonist candidate, SB 11285, at the American Society of Clinical Oncology Annual Meeting, which will be conducted virtually from May 29-June 2, 2020.

Centene Corporation, which offers Medicare Advantage plans nationally through the WellCare and Allwell brands and locally through the Health Net brand, announced new efforts to help support its nearly 1 million Medicare Advantage members during the COVID-19 pandemic.

On track to report progression free survival and overall survival data from triple combination arm of ongoing COMBAT/KEYNOTE-202 Phase 2a trial in mid-2020

Evogene Ltd., a leading computational biology company targeting to revolutionize life-science product development across several market segments, announces its rebranding.

Phase 3b Study Evaluated Efficacy and Safety of ARISTADA® 2-month Dose, Together With ARISTADA INITIO® One-day Initiation Regimen, in Patients Hospitalized for Acute Schizophrenia

Nancy Wysenski, a Seasoned Pharmaceutical Executive with Rare Disease and Commercialization Experience, Appointed as a New Director

Publication in Nature Communications demonstrates generation of robust neutralizing antibodies and T cell responses against SARS-CoV-2